1
|
Nguyen DT, Ngo TH, Tran MT, Nguyen HTT, Ho HT, Nguyen DV, Nguyen TT, Ly KD, Nguyen TT, Vuong TT, Tran HV. 11-Azaartemisninin derivatives bearing halogenated aromatic moieties: Potent anticancer agents with high tumor selectivity. Bioorg Med Chem Lett 2024; 113:129969. [PMID: 39299490 DOI: 10.1016/j.bmcl.2024.129969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2024] [Revised: 08/26/2024] [Accepted: 09/15/2024] [Indexed: 09/22/2024]
Abstract
While artemisinin and its derivatives, including 11-azaartemisinin-based compounds, have shown promising anticancer activity, the integration of halogens into aromatic structures can amplify drug potency, metabolic stability, and selectivity. Herein, we present the synthesis of new novel 11-azaartemisinin derivatives bearing halogenated aromatic moieties connected via 1,2,3-triazole bridges and evaluate their anticancer activities against three human tumor cell lines: epidermoid carcinoma (KB), hepatoma carcinoma (HepG2), and human lung adenocarcinoma (A549). Among the synthesized compounds, 6 of them (8c-h) displayed good to excellent antiproliferative activity in the low micromolar range across all three human cancer cell lines. In general, the m-bromide (8c) and m-iodide (8d) compounds exhibited superior anticancer activities compared to their o- and p-analogs, as well as the m-chloride and m-fluoride compounds. The most promising m-Br compound (8c) displayed 50 % inhibition of KB, HepG2, and A549 cell growth at concentrations of 7.7, 42.5, and 15.5 μM, respectively. Notably, the m-Br compound (8c) exhibited approximately 32-, 6-, and 16-fold lower activity in normal cells (Hek293) compared to KB, HepG2, and A549 tumor cells, respectively, indicating a significant tumor-selective.
Collapse
Affiliation(s)
- Dung Tien Nguyen
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam.
| | - Thuong Hanh Ngo
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Mai Thanh Tran
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Hao Thi Thanh Nguyen
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Hien Thanh Ho
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Dat Van Nguyen
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Tinh Thi Nguyen
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Khang Duc Ly
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Thao Thi Nguyen
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Tam Thi Vuong
- Vietnam University of Traditional Medicine, No. 2 Tran Phu St., Ha Dong, Hanoi 12110, Viet Nam
| | - Hung-Vu Tran
- NTT Hi-Tech Institute, Nguyen Tat Thanh University, 298-300A Nguyen Tat Thanh Street, District 4, Ho Chi Minh City 7280, Viet Nam; Department of Chemistry, University of Houston, 4800 Calhoun Road, Houston, TX 77204-5003, United States.
| |
Collapse
|
2
|
Karnatak M, Yadav P, Rathi K, Shukla M, Dugam P, Suthakaran S, Rawat V, Hassam M, Pandey A, Maurya RA, Sen D, Debnath S, Das A, Mukhija A, Verma VP. New hydrazide derivatives of N-amino-11-azaartemisinin as promising epidermal growth factor receptor inhibitors for therapeutic development in triple-negative breast cancer. Arch Pharm (Weinheim) 2024:e2400466. [PMID: 39267485 DOI: 10.1002/ardp.202400466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2024] [Revised: 08/26/2024] [Accepted: 08/27/2024] [Indexed: 09/17/2024]
Abstract
Triple-negative breast cancer (TNBC) treatments, such as DNA-damaging agents like carboplatin, pose considerable human toxicity and may contribute to cancer relapse. Artemisinin derivatives offer a less toxic alternative; however, their specific role in TNBC management remains to be established. To address this gap, computational models were employed to design and evaluate artemisinin-based prototypes as potential TNBC therapeutics, aiming to provide safer and more effective treatment options for this aggressive cancer subtype. Among the series of hydrazide derivatives of azaartemisinin (10a-l) reported herein, compound 10j emerged as the most promising, exhibiting notable cytotoxicity with IC50 values of 1.74 and 1.64 µM against MDA-MB-231 and MDA-MB-468 cells, respectively. The clinically useful drug doxorubicin provided IC50 values of 0.29 and 0.29 µM against MDA-MB-231 and MDA-MB-468 cells, while artemisinin provided IC50 values of 107.30 and 116.60 µM, respectively. Furthermore, putative interactions between the synthesized compounds and the epidermal growth factor receptor (EGFR) were identified using molecular docking studies, suggesting a possible mechanism for their anticancer effect. Additionally, to determine the thermodynamic parameters of the interactions between artemisinin, azaartemisinin, and biomolecules, isothermal titration calorimetry experiments were performed. The binding constant value on the order of 104 indicates a comparatively stronger binding affinity of azaartemisinin with human serum albumin (HSA) compared to artemisinin with HSA. These findings support the potential of azaartemisinin derivatives as promising EGFR inhibitors for therapeutic development in TNBC, offering a new avenue for less toxic and more effective cancer treatments.
Collapse
Affiliation(s)
- Manvika Karnatak
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Priyanka Yadav
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Komal Rathi
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Monika Shukla
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Prachi Dugam
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India
| | - Shruthi Suthakaran
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India
| | - Varun Rawat
- Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Mohammad Hassam
- Chemveda Life Sciences Pvt. Ltd., Hyderabad, Telangana, India
| | - Aditi Pandey
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Ram Awatar Maurya
- Applied Organic Chemistry Group, Chemical Science and Technology Division, CSIR-North East Institute of Science & Technology, Jorhat, Assam, India
| | - Debanjan Sen
- BCDA College of Pharmacy & Technology, Hridaypur, Barasat, Kolkata, West Bengal, India
| | - Sudhan Debnath
- Department of Chemistry, Netaji Subhash Mahavidyalaya, Udaipur, Tripura, India
| | - Amitava Das
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India
| | - Achal Mukhija
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
| | - Ved Prakash Verma
- Department of Chemistry, Banasthali University, Banasthali Newai, Rajasthan, India
- Department of Education in Science and Mathematics (DESM), Regional Institute of Education, Bhubaneshwar, Odisha, India
| |
Collapse
|
3
|
Dresler E, Wróblewska A, Jasiński R. Understanding the Regioselectivity and the Molecular Mechanism of [3 + 2] Cycloaddition Reactions between Nitrous Oxide and Conjugated Nitroalkenes: A DFT Computational Study. Molecules 2022; 27:molecules27238441. [PMID: 36500530 PMCID: PMC9738823 DOI: 10.3390/molecules27238441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Revised: 11/26/2022] [Accepted: 11/29/2022] [Indexed: 12/03/2022] Open
Abstract
Regiochemical aspects and the molecular mechanism of the [3 + 2] cycloaddition between nitrous oxide and conjugated nitroalkenes were evaluated on the basis of the wb97xd/6-311 + G(d) (PCM) computational study. It was found that, independently of the nature of the nitroalkene, all considered processes are realized via polar, single-step mechanisms. All attempts at the localization of hypothetical zwitterionic intermediates were unsuccessful. Additionally, the DFT computational study suggested that, in the course of the reaction, the formation of respective Δ2-4-nitro-4-R1-5-R2-1-oxa-2,3-diazolines was preferred from the kinetic point of view.
Collapse
Affiliation(s)
- Ewa Dresler
- Łukasiewicz Research Network, Institute of Heavy Organic Synthesis “Blachownia”, Energetyków 9, 47-225 Kędzierzyn-Koźle, Poland
| | - Aneta Wróblewska
- Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland
| | - Radomir Jasiński
- Institute of Organic Chemistry and Technology, Cracow University of Technology, Warszawska 24, 31-155 Cracow, Poland
- Correspondence:
| |
Collapse
|
4
|
Zhang S, Yi C, Li WW, Luo Y, Wu YZ, Ling HB. The current scenario on anticancer activity of artemisinin metal complexes, hybrids, and dimers. Arch Pharm (Weinheim) 2022; 355:e2200086. [PMID: 35484335 DOI: 10.1002/ardp.202200086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Revised: 03/28/2022] [Accepted: 03/31/2022] [Indexed: 11/09/2022]
Abstract
Cancer, the most significant cause of morbidity and mortality, has already posed a heavy burden on health care systems globally. In recent years, cancer treatment has made a significant breakthrough, but cancer cells inevitably acquire resistance, and the efficacy of the treatment is greatly reduced as the tumor progresses. To overcome the above issues, novel chemotherapeutics are needed urgently. Artemisinin and its derivatives-sesquiterpene lactone compounds possessing a unique peroxy bridge moiety-exhibit excellent safety and tolerability profiles. Mechanistically, artemisinin derivatives can promote cancer cell apoptosis, induce cell cycle arrest and autophagy, and inhibit cancer cell invasion and migration. Accordingly, artemisinin derivatives demonstrate promising anticancer efficacy both in vitro and in vivo, and even in clinical Phase I/II trials. The purpose of the present review article is to provide an emphasis on the current scenario (January 2017-January 2022) of artemisinin derivatives with potential anticancer activity, inclusive of artemisinin metal complexes, hybrids, and dimers. The structure-activity relationships and mechanisms of action are also discussed to facilitate the further rational design of more effective candidates.
Collapse
Affiliation(s)
- Shu Zhang
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| | - Chuan Yi
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| | - Wei-Wei Li
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| | - Yang Luo
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| | - Yi-Zhe Wu
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| | - Hai-Bo Ling
- Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, People's Republic of China
| |
Collapse
|